HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A

Virology

Volumn 440, Issue 2, 2013, Pages 190-203

  Bolduan, Sebastian ^a   Hubel, Philipp ^a   Reif, Tatjana ^a   Lodermeyer, Veronika ^a   Höhne, Kristin ^d   Fritz, Joëlle V ^c   Sauter, Daniel ^b   Kirchhoff, Frank ^b   Fackler, Oliver T ^c   Schindler, Michael ^d   Schubert, Ulrich ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

HIV 1; N linked glycosylation; NTB A; Pulse chase; SIV; SLAMF6; Tetherin; Vpu

Indexed keywords

CD4 ANTIGEN; GLYCOPEPTIDASE F; NATURAL KILLER CELL RECEPTOR NK T CELL B CELL ANTIGEN; PEPTIDASE; TETHERIN PROTEIN; TUNICAMYCIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN; VPU PROTEIN;

ALPHA HELIX; ARTICLE; CELL SURFACE; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; GOLGI COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; VIRUS STRAIN;

ANTIGENS, CD; CELL LINE; DOWN-REGULATION; GENE EXPRESSION; GLYCOSYLATION; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; IMMUNE EVASION; PROTEIN TRANSPORT; RECEPTORS, CELL SURFACE; VIRAL REGULATORY AND ACCESSORY PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84876794923     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.02.021     Document Type: Article

References (58)

1. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59(2):284-291.
2. Banning C., Votteler J., Hoffmann D., Koppensteiner H., Warmer M., Reimer R., Kirchhoff F., Schubert U., Hauber J., Schindler M. A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells. PLoS One 2010, 5(2):e9344.
3. Binette J., Dube M., Mercier J., Halawani D., Latterich M., Cohen E.A. Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. Retrovirology 2007, 4:75.
4. Bolduan S., Votteler J., Lodermeyer V., Greiner T., Koppensteiner H., Schindler M., Thiel G., Schubert U. Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317. Virology 2011, 416(1-2):75-85.
5. Bottino C., Falco M., Parolini S., Marcenaro E., Augugliaro R., Sivori S., Landi E., Biassoni R., Notarangelo L.D., Moretta L., Moretta A. NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J. Exp. Med. 2001, 194(3):235-246.
6. Butticaz C., Michielin O., Wyniger J., Telenti A., Rothenberger S. Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation. J. Virol. 2007, 81(3):1502-1505.
7. Chen M.Y., Maldarelli F., Karczewski M.K., Willey R.L., Strebel K. Human immunodeficiency virus type 1 Vpu protein induces degradation of CD4 in vitro: the cytoplasmic domain of CD4 contributes to Vpu sensitivity. J. Virol. 1993, 67(7):3877-3884.
8. Cohen E.A., Terwilliger E.F., Sodroski J.G., Haseltine W.A. Identification of a protein encoded by the vpu gene of HIV-1. Nature 1988, 334(6182):532-534.
9. Cohen G.B., Gandhi R.T., Davis D.M., Mandelboim O., Chen B.K., Strominger J.L., Baltimore D. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999, 10(6):661-671.
10. Douglas J.L., Viswanathan K., McCarroll M.N., Gustin J.K., Fruh K., Moses A.V. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J. Virol. 2009, 83(16):7931-7947.
11. Dube M., Roy B.B., Guiot-Guillain P., Binette J., Mercier J., Chiasson A., Cohen E.A. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 2010, 6(4):e1000856.
12. Dube M., Roy B.B., Guiot-Guillain P., Mercier J., Binette J., Leung G., Cohen E.A. Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J. Virol. 2009, 83(9):4574-4590.
13. Elbein A.D. Glycosylation inhibitors for N-linked glycoproteins. Methods Enzymol. 1987, 138:661-709.
14. Ewart G.D., Sutherland T., Gage P.W., Cox G.B. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J. Virol. 1996, 70(10):7108-7115.
15. Flaig R.M., Stark S., Watzl C. Cutting edge: NTB-A activates NK cells via homophilic interaction. J. Immunol. 2004, 172(11):6524-6527.
16. Fullekrug J., Scheiffele P., Simons K. VIP36 localisation to the early secretory pathway. J. Cell Sci. 1999, 112(Pt 17):2813-2821.
17. Goffinet C., Homann S., Ambiel I., Tibroni N., Rupp D., Keppler O.T., Fackler O.T. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J. Virol. 2010, 84(8):4089-4094.
18. Iwabu Y., Fujita H., Kinomoto M., Kaneko K., Ishizaka Y., Tanaka Y., Sata T., Tokunaga K. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J. Biol. Chem. 2009, 284(50):35060-35072.
19. Klimkait T., Strebel K., Hoggan M.D., Martin M.A., Orenstein J.M. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J. Virol. 1990, 64(2):621-629.
20. Koppensteiner H., Banning C., Schneider C., Hohenberg H., Schindler M. Macrophage internal HIV-1 is protected from neutralizing antibodies. J. Virol. 2012, 86(5):2826-2836.
21. Kuhl B.D., Cheng V., Donahue D.A., Sloan R.D., Liang C., Wilkinson J., Wainberg M.A. The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism. PLoS One 2011, 6(11):e27660.
22. Kupzig S., Korolchuk V., Rollason R., Sugden A., Wilde A., Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 2003, 4(10):694-709.
23. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227(5259):680-685.
24. Magadan J.G., Perez-Victoria F.J., Sougrat R., Ye Y., Strebel K., Bonifacino J.S. Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog. 2010, 6(4):e1000869.
25. Maldarelli F., Chen M.Y., Willey R.L., Strebel K. Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J. Virol. 1993, 67(8):5056-5061.
26. Mangeat B., Gers-Huber G., Lehmann M., Zufferey M., Luban J., Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 2009, 5(9):e1000574.
27. Marassi F.M., Ma C., Gratkowski H., Straus S.K., Strebel K., Oblatt-Montal M., Montal M., Opella S.J. Correlation of the structural and functional domains in the membrane protein Vpu from HIV-1. Proc. Natl. Acad. Sci. U S A 1999, 96(25):14336-14341.
28. Margottin F., Bour S.P., Durand H., Selig L., Benichou S., Richard V., Thomas D., Strebel K., Benarous R. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell 1998, 1(4):565-574.
29. Matusali G., Potesta M., Santoni A., Cerboni C., Doria M. The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR. J. Virol. 2012, 86(8):4496-4504.
30. Misumi Y., Miki K., Takatsuki A., Tamura G., Ikehara Y. Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J. Biol. Chem. 1986, 261(24):11398-11403.
31. Mitchell R.S., Katsura C., Skasko M.A., Fitzpatrick K., Lau D., Ruiz A., Stephens E.B., Margottin-Goguet F., Benarous R., Guatelli J.C. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog. 2009, 5(5):e1000450.
32. Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451(7177):425-430.
33. Norris G.E., Stillman T.J., Anderson B.F., Baker E.N. The three-dimensional structure of PNGase F, a glycosylasparaginase from Flavobacterium meningosepticum. Structure 1994, 2(11):1049-1059.
34. Pacyniak E., Gomez M.L., Gomez L.M., Mulcahy E.R., Jackson M., Hout D.R., Wisdom B.J., Stephens E.B. Identification of a region within the cytoplasmic domain of the subtype B Vpu protein of human immunodeficiency virus type 1 (HIV-1) that is responsible for retention in the golgi complex and its absence in the Vpu protein from a subtype C HIV-1. AIDS Res. Hum. Retroviruses 2005, 21(5):379-394.
35. Perez-Caballero D., Zang T., Ebrahimi A., McNatt M.W., Gregory D.A., Johnson M.C., Bieniasz P.D. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139(3):499-511.
36. Rocks O., Gerauer M., Vartak N., Koch S., Huang Z.P., Pechlivanis M., Kuhlmann J., Brunsveld L., Chandra A., Ellinger B., Waldmann H., Bastiaens P.I. The palmitoylation machinery is a spatially organizing system for peripheral membrane proteins. Cell 2010, 141(3):458-471.
37. Rong L., Zhang J., Lu J., Pan Q., Lorgeoux R.P., Aloysius C., Guo F., Liu S.L., Wainberg M.A., Liang C. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J. Virol. 2009, 83(15):7536-7546.
38. Sauter D., Schindler M., Specht A., Landford W.N., Munch J., Kim K.A., Votteler J., Schubert U., Bibollet-Ruche F., Keele B.F., Takehisa J., Ogando Y., Ochsenbauer C., Kappes J.C., Ayouba A., Peeters M., Learn G.H., Shaw G., Sharp P.M., Bieniasz P., Hahn B.H., Hatziioannou T., Kirchhoff F. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6(5):409-421.
39. Schindler M., Rajan D., Banning C., Wimmer P., Koppensteiner H., Iwanski A., Specht A., Sauter D., Dobner T., Kirchhoff F. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirology 2010, 7:1.
40. Schindler M., Wurfl S., Benaroch P., Greenough T.C., Daniels R., Easterbrook P., Brenner M., Munch J., Kirchhoff F. Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles. J. Virol. 2003, 77(19):10548-10556.
41. Schmidt S., Fritz J.V., Bitzegeio J., Fackler O.T., Keppler O.T. HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. MBio 2011, 2(3):e00036-11.
42. Schubert U., Anton L.C., Bacik I., Cox J.H., Bour S., Bennink J.R., Orlowski M., Strebel K., Yewdell J.W. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J. Virol. 1998, 72(3):2280-2288.
43. Schubert U., Bour S., Ferrer-Montiel A.V., Montal M., Maldarell F., Strebel K. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J. Virol. 1996, 70(2):809-819.
44. Schubert U., Ferrer-Montiel A.V., Oblatt-Montal M., Henklein P., Strebel K., Montal M. Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett. 1996, 398(1):12-18.
45. Schubert U., Henklein P., Boldyreff B., Wingender E., Strebel K., Porstmann T. The human immunodeficiency virus type 1 encoded Vpu protein is phosphorylated by casein kinase-2 (CK-2) at positions Ser52 and Ser56 within a predicted alpha-helix-turn-alpha-helix-motif. J. Mol. Biol. 1994, 236(1):16-25.
46. Shah A.H., Sowrirajan B., Davis Z.B., Ward J.P., Campbell E.M., Planelles V., Barker E. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe 2010, 8(5):397-409.
47. Shikano S., Li M. Membrane receptor trafficking: evidence of proximal and distal zones conferred by two independent endoplasmic reticulum localization signals. Proc. Natl. Acad. Sci. U S A 2003, 100(10):5783-5788.
48. Skasko M., Tokarev A., Chen C.C., Fischer W.B., Pillai S.K., Guatelli J. BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action. Virology 2011, 411(1):65-77.
49. Sowrirajan B., Barker E. The natural killer cell cytotoxic function is modulated by HIV-1 accessory proteins. Viruses 2011, 3(7):1091-1111.
50. Strebel K., Klimkait T., Martin M.A. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 1988, 241(4870):1221-1223.
51. Tkacz J.S., Lampen O. Tunicamycin inhibition of polyisoprenyl N-acetylglucosaminyl pyrophosphate formation in calf-liver microsomes. Biochem. Biophys. Res. Commun. 1975, 65(1):248-257.
52. Valdez P.A., Wang H., Seshasayee D., van Lookeren Campagne M., Gurney A., Lee W.P., Grewal I.S. NTB-A, a new activating receptor in T cells that regulates autoimmune disease. J. Biol. Chem. 2004, 279(18):18662-18669.
53. Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3(4):245-252.
54. Vigan R., Neil S.J. Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. J. Virol. 2011, 85(19):9737-9748.
55. Vincent M.J., Abdul Jabbar M. The human immunodeficiency virus type 1 Vpu protein: a potential regulator of proteolysis and protein transport in the mammalian secretory pathway. Virology 1995, 213(2):639-649.
56. Ward J., Davis Z., DeHart J., Zimmerman E., Bosque A., Brunetta E., Mavilio D., Planelles V., Barker E. HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog. 2009, 5(10):e1000613.
57. Willey R.L., Maldarelli F., Martin M.A., Strebel K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J. Virol. 1992, 66(12):7193-7200.
58. Zhong M.C., Veillette A. Control of T lymphocyte signaling by Ly108, a signaling lymphocytic activation molecule family receptor implicated in autoimmunity. J. Biol. Chem. 2008, 283(28):19255-19264.